These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

138 related items for PubMed ID: 9795924

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Interferon alfacon-1: a review of its pharmacology and therapeutic efficacy in the treatment of chronic hepatitis C.
    Melian EB, Plosker GL.
    Drugs; 2001; 61(11):1661-91. PubMed ID: 11577799
    [Abstract] [Full Text] [Related]

  • 24. High dose consensus interferon in nonresponders to interferon alpha-2b and ribavirin with chronic hepatitis C.
    Moskovitz DN, Manoharan P, Heathcote EJ.
    Can J Gastroenterol; 2003 Aug; 17(8):479-82. PubMed ID: 12945008
    [Abstract] [Full Text] [Related]

  • 25. Randomized controlled trial of recombinant alpha-2a-interferon for chronic hepatitis C. Comparison of alanine aminotransferase normalization versus loss of HCV RNA and anti-HCV IgM.
    Douglas DD, Rakela J, Lin HJ, Hollinger FB, Taswell HF, Czaja AJ, Gross JB, Anderson ML, Parent K, Fleming CR.
    Dig Dis Sci; 1993 Apr; 38(4):601-7. PubMed ID: 8384978
    [Abstract] [Full Text] [Related]

  • 26. Pegylated interferon alfa-2b plus ribavirin in the retreatment of interferon-ribavirin nonresponder patients.
    Taliani G, Gemignani G, Ferrari C, Aceti A, Bartolozzi D, Blanc PL, Capanni M, Esperti F, Forte P, Guadagnino V, Mari T, Marino N, Milani S, Pasquazzi C, Rosina F, Tacconi D, Toti M, Zignego AL, Messerini L, Stroffolini T, Nonresponder Retreatment Group.
    Gastroenterology; 2006 Apr; 130(4):1098-106. PubMed ID: 16618404
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. alpha-Interferon retreatment of patients with chronic hepatitis C.
    Rabinovitz M, Block G, Finkelstein SD.
    Am J Gastroenterol; 1996 Aug; 91(8):1523-6. PubMed ID: 8759654
    [Abstract] [Full Text] [Related]

  • 29. Earlier loss of hepatitis C virus RNA in interferon therapy can predict a long-term response in chronic hepatitis C.
    Kakumu S, Aiyama T, Okumura A, Iwata K, Ishikawa T, Yoshioka K.
    J Gastroenterol Hepatol; 1997 Jun; 12(6):468-72. PubMed ID: 9195406
    [Abstract] [Full Text] [Related]

  • 30. Different doses of consensus interferon plus ribavirin in patients with hepatitis C virus genotype 1 relapsed after interferon monotherapy: a randomized controlled trial.
    Alaimo G, Di Marco V, Ferraro D, Di Stefano R, Porrovecchio S, D'Angelo F, Calvaruso V, Craxì A, Almasio PL.
    World J Gastroenterol; 2006 Nov 14; 12(42):6861-4. PubMed ID: 17106937
    [Abstract] [Full Text] [Related]

  • 31. Polyunsaturated phosphatidyl-choline and interferon alpha for treatment of chronic hepatitis B and C: a multi-center, randomized, double-blind, placebo-controlled trial. Leich Study Group.
    Niederau C, Strohmeyer G, Heintges T, Peter K, Göpfert E.
    Hepatogastroenterology; 1998 Nov 14; 45(21):797-804. PubMed ID: 9684137
    [Abstract] [Full Text] [Related]

  • 32. Recent i.v.-drug users with chronic hepatitis C can be efficiently treated with daily high dose induction therapy using consensus interferon: an open-label pilot study.
    Witthoeft T, Fuchs M, Ludwig D.
    World J Gastroenterol; 2007 Jan 28; 13(4):579-84. PubMed ID: 17278224
    [Abstract] [Full Text] [Related]

  • 33. Re-treatment of chronic hepatitis C with consensus interferon .
    Heathcote EJ, Keeffe EB, Lee SS, Feinman SV, Tong MJ, Reddy KR, Albert DG, Witt K, Blatt LM.
    Hepatology; 1998 Apr 28; 27(4):1136-43. PubMed ID: 9537455
    [Abstract] [Full Text] [Related]

  • 34. Interferon-alpha-2b plus ribavirin: a review of its use in the management of chronic hepatitis C.
    Scott LJ, Perry CM.
    Drugs; 2002 Apr 28; 62(3):507-56. PubMed ID: 11827565
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Disappearance of hepatitis C virus RNA in plasma during interferon alpha-2B treatment in hemophilia patients.
    Bresters D, Mauser-Bunschoten EP, Cuypers HT, Lelie PN, Han JH, Jansen PL, Houghton M, Reesink HW.
    Scand J Gastroenterol; 1992 Apr 28; 27(3):166-8. PubMed ID: 1323873
    [Abstract] [Full Text] [Related]

  • 38. Treatment of chronic hepatitis C with high-dose interferon alpha-2b. A multicenter study.
    Iino S, Hino K, Kuroki T, Suzuki H, Yamamoto S.
    Dig Dis Sci; 1993 Apr 28; 38(4):612-8. PubMed ID: 8384980
    [Abstract] [Full Text] [Related]

  • 39. Alpha but not beta interferon is useful in chronic active hepatitis due to hepatitis C virus. A prospective, double-blind, randomized study.
    Villa E, Trande P, Grottola A, Buttafoco P, Rebecchi AM, Stroffolini T, Callea F, Merighi A, Camellini L, Zoboli P, Cosenza R, Miglioli L, Loria P, Iori R, Carulli N, Manenti F.
    Dig Dis Sci; 1996 Jun 28; 41(6):1241-7. PubMed ID: 8654159
    [Abstract] [Full Text] [Related]

  • 40. Treatment of chronic hepatitis C with interferon-alpha. Clinical histological and virological implications.
    Olaso V, Córdoba J, Berenguer M, Prieto M, Lainez B, Argüello L, Valverde J, Pascual S, Gobernado M, Berenguer J.
    Rev Esp Enferm Dig; 1997 Jul 28; 89(7):531-50. PubMed ID: 9265839
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.